Clevidipine - Chiesi Farmaceutici
Alternative Names: CHF 6725; Clevelox; Clevidipine butyrate; CleviprexLatest Information Update: 09 Nov 2020
At a glance
- Originator AstraZeneca
- Developer Chiesi Farmaceutici; Chiesi USA
- Class Antihypertensives; Dihydropyridines
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension; Perioperative hypertension
Most Recent Events
- 19 Oct 2020 Chiesi USA withdraw a phase III PRONTO II trial in Hypertension in USA as company decided to not move forward with study(NCT04592380)
- 03 Jul 2019 Clevidipine is not yet available for Hypertension in New Zealand
- 03 Jul 2019 Clevidipine is not yet available for Perioperative hypertension in Canada